<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01449747</url>
  </required_header>
  <id_info>
    <org_study_id>CMCENDO-01</org_study_id>
    <nct_id>NCT01449747</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics Study of Dipeptidyl Peptidase 4 Inhibitor to Control Type 2 Diabetes Mellitus</brief_title>
  <official_title>Mechanism of Reduced Response to DPP-4 Inhibitor in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Catholic University of Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm the mechanism of reduced response to DPP-4 inhibitor
      in some patients with type 2 diabetes and evaluate appropriate patients to treat with DPP-4
      inhibitor
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sitagliptin, a DPP-4 inhibitor was used as an incretin enhancer in clinical practice first.
      In clinical trials, sitagliptin showed effective control of blood glucose level in type 2
      diabetes and 100 mg once daily with metformin was similar to sulfonylurea (glipizide) with
      metformin in lowering HbA1c. Mostly in practice, stable blood glucose levels were maintained
      after change of sulfonylurea to sitagliptin in type 2 diabetes treatment. However, in some
      cases, there were abrupt severe hyperglycemia and uncontrolled blood glucose level after drug
      change to sitagliptin.

      Several mechanism could be considered for reduced response to DPP-4 inhibitor in some type 2
      diabetes patients. Firstly, significantly reduced secretion of glucagon-like peptide 1
      (GLP-1) more than expected in diabetes or functional defect of GLP-1 activity could be the
      mechanism of loss of GLP-1 effect irrespective of DPP-4. Secondly, mutation or functional
      defect of DPP-4 enzyme could not be inhibited by DPP-4 inhibitor. Thirdly, GLP-1 receptor
      mutation or other defect in β-cell responsiveness to GLP-1 leads to reduction of response to
      DPP-4 inhibitor.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Concentration of Active Glucagon-like Peptide 1 (GLP-1) Before and After Sitagliptin Treatment</measure>
    <time_frame>0, 15, 30, 45, 60, 90, 120, 180 min pre and post-dose</time_frame>
    <description>Plasma concentrations of active GLP-1 were measured at 0, 15, 30, 45, 60, 90, 120 and 180 min during the meal tolerance test (MTT). Second measurement of active GLP-1 were measured with MTT after taking sitagliptin 100 mg 1 hour before the test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Concentration of Total GLP-1 Before and After Sitagliptin Treatment</measure>
    <time_frame>0, 15, 30, 45, 60, 90, 120, 180 min pre and post-dose</time_frame>
    <description>Plasma concentrations of total GLP-1 were measured at 0, 15, 30, 45, 60, 90, 120 and 180 min during the meal tolerance test. Second measurement of total GLP-1 were measured with MTT after taking sitagliptin 100 mg 1 hour before the test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Concentration of Total Glucose-dependent Insulinotropic Polypeptide (GIP) Before and After Sitagliptin Treatment</measure>
    <time_frame>0, 15, 30, 45, 60, 90, 120, 180 min pre and post-dose</time_frame>
    <description>Plasma concentrations of total GIP were measured at 0, 15, 30, 45, 60, 90, 120 and 180 min during the meal tolerance test. Second measurement of total GIP were measured with MTT after taking sitagliptin 100 mg 1 hour before the test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in AUC of Active GLP-1, Total GLP-1 and Total GIP Between Before and After Sitagliptin Treatment</measure>
    <time_frame>0, 15, 30, 45, 60, 90, 120, 180 min pre and post-dose</time_frame>
    <description>Plasma concentrations of active GLP-1, total GLP-1 and total GIP were measured at 0, 15, 30, 45, 60, 90, 120 and 180 min during the meal tolerance test. Second measurements were measured with MTT after taking sitagliptin 100 mg 1 hour before the test. Comparisons were made using Area under the curve (AUC) values and incremental area under the curve (ΔAUC) of active GLP-1, total GLP-1 and total GIP before and after the addition of sitagliptin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences of DPP-4 Activity After Sitagliptin Treatment Between Responder and Non-responder Groups</measure>
    <time_frame>0, 15, 30, 45, 60 min post-dose</time_frame>
    <description>The DPP-4 activity was measured at baseline and 0, 15, 30, 45 and 60 min during the meal tolerance test. Second measurement of DPP-4 activity was measured with MTT after taking sitagliptin 100 mg 1 hour before the test. Plasma DPP-4 activity during meal tolerance test is expressed as percentage activity relative to baseline. DPP-4 activity % was calculated using the following formula : (DPP-4 activity at time t / Baseline DPP-4 activity) × 100.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>study group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sitagliptin hypo-response patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>sitagliptin response patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>Sitagliptin (100mg, per oral) once a day.</description>
    <arm_group_label>study group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetic patients with less than 15 yrs of disease duration

          -  BMI between 22-27 kg/m2

          -  HbA1c ≤ 9% at recruitment

               1. Study group

        After change sulfonylurea to sitagliptin in case of metformin and sulfonylurea therapy

          1. Increase of fasting blood glucose over 20 mg/dL or postprandial glucose over 30 mg/dL
             within several days or

          2. Increase of HbA1c over 1% within 2-3 months without abrupt increase of blood glucose
             levels within several days

               -  Sulfonylurea dose : less than glimepiride 4mg or gliclazide 120mg or
                  glibenclamide 10mg

               -  Metformin dose : 500~2000mg

          3. Reduced response to sitagliptin should be made a decision by investigators after
             understanding the condition of patients surely.

        2. Control group

          -  Age, sex, BMI matched patients with same condition of study patients

          -  After change sulfonylurea to sitagliptin in case of metformin plus sulfonylurea
             therapy, no change of blood glucose levels like above or stable HbA1c change within 1%
             within 2-3 months

        Exclusion Criteria:

          -  Other causes of increase of blood glucose levels except drug change

          -  Patients with history of insulin treatment

          -  Patients taking thiazolidinediones, alpha-glucosidase inhibitors, GLP-1 analogue or
             DPP-4 inhibitors

          -  Patients with renal, hepatic dysfunction

          -  Patients with diabetic complications such as coronary heart disease, cerebrovascular
             disease, proliferative diabetic retinopathy or diabetic gastroparesis

          -  Patients taking medications affecting glucose level
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ji Hyun Kim, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Catholic University of Korea; St.Paul's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>130-709</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea; Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2011</study_first_submitted>
  <study_first_submitted_qc>October 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2011</study_first_posted>
  <results_first_submitted>August 23, 2015</results_first_submitted>
  <results_first_submitted_qc>November 10, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 14, 2015</results_first_posted>
  <last_update_submitted>November 10, 2015</last_update_submitted>
  <last_update_submitted_qc>November 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Catholic University of Korea</investigator_affiliation>
    <investigator_full_name>Ji Hyun Kim</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Type 2 diabetes mellitus</keyword>
  <keyword>Dipeptidyl peptidase IV inhibitors</keyword>
  <keyword>Glucagon-like peptide 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Non-responder</title>
          <description>Sitagliptin non-response patients</description>
        </group>
        <group group_id="P2">
          <title>Responder</title>
          <description>Sitagliptin response patients</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Non-responder</title>
          <description>Sitagliptin non-response patients</description>
        </group>
        <group group_id="B2">
          <title>Responder</title>
          <description>Sitagliptin response patients</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.8" spread="5.7"/>
                    <measurement group_id="B2" value="57.4" spread="7.0"/>
                    <measurement group_id="B3" value="58.1" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of diabetes mellitus</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.2" spread="5.5"/>
                    <measurement group_id="B2" value="5.2" spread="2.7"/>
                    <measurement group_id="B3" value="6.2" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.1" spread="1.7"/>
                    <measurement group_id="B2" value="24.4" spread="3.8"/>
                    <measurement group_id="B3" value="24.8" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.7" spread="0.6"/>
                    <measurement group_id="B2" value="6.6" spread="0.7"/>
                    <measurement group_id="B3" value="7.2" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Plasma Concentration of Active Glucagon-like Peptide 1 (GLP-1) Before and After Sitagliptin Treatment</title>
        <description>Plasma concentrations of active GLP-1 were measured at 0, 15, 30, 45, 60, 90, 120 and 180 min during the meal tolerance test (MTT). Second measurement of active GLP-1 were measured with MTT after taking sitagliptin 100 mg 1 hour before the test.</description>
        <time_frame>0, 15, 30, 45, 60, 90, 120, 180 min pre and post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-responder</title>
            <description>Sitagliptin non-response patients</description>
          </group>
          <group group_id="O2">
            <title>Responder</title>
            <description>Sitagliptin response patients</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of Active Glucagon-like Peptide 1 (GLP-1) Before and After Sitagliptin Treatment</title>
          <description>Plasma concentrations of active GLP-1 were measured at 0, 15, 30, 45, 60, 90, 120 and 180 min during the meal tolerance test (MTT). Second measurement of active GLP-1 were measured with MTT after taking sitagliptin 100 mg 1 hour before the test.</description>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline 0 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="6.6"/>
                    <measurement group_id="O2" value="6.1" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline 15 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" spread="8.0"/>
                    <measurement group_id="O2" value="14.1" spread="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline 30 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" spread="10.3"/>
                    <measurement group_id="O2" value="14.3" spread="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline 45 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7" spread="8.2"/>
                    <measurement group_id="O2" value="9.3" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline 60 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7" spread="6.8"/>
                    <measurement group_id="O2" value="8.4" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline 90 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" spread="5.4"/>
                    <measurement group_id="O2" value="7.6" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline 120 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" spread="6.8"/>
                    <measurement group_id="O2" value="7.4" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline 180 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6" spread="8.7"/>
                    <measurement group_id="O2" value="7.1" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-dose 0 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" spread="9.4"/>
                    <measurement group_id="O2" value="10.5" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-dose 15 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" spread="16.0"/>
                    <measurement group_id="O2" value="26.0" spread="39.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-dose 30 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.4" spread="11.0"/>
                    <measurement group_id="O2" value="34.3" spread="53.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-dose 45 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.4" spread="11.3"/>
                    <measurement group_id="O2" value="27.1" spread="37.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-dose 60 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.7" spread="11.3"/>
                    <measurement group_id="O2" value="22.8" spread="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-dose 90 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.3" spread="10.8"/>
                    <measurement group_id="O2" value="16.5" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-dose 120 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0" spread="10.8"/>
                    <measurement group_id="O2" value="16.4" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-dose 180 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5" spread="8.3"/>
                    <measurement group_id="O2" value="13.5" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Differences of DPP-4 Activity After Sitagliptin Treatment Between Responder and Non-responder Groups</title>
        <description>The DPP-4 activity was measured at baseline and 0, 15, 30, 45 and 60 min during the meal tolerance test. Second measurement of DPP-4 activity was measured with MTT after taking sitagliptin 100 mg 1 hour before the test. Plasma DPP-4 activity during meal tolerance test is expressed as percentage activity relative to baseline. DPP-4 activity % was calculated using the following formula : (DPP-4 activity at time t / Baseline DPP-4 activity) × 100.</description>
        <time_frame>0, 15, 30, 45, 60 min post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-responder</title>
            <description>Sitagliptin non-response patients</description>
          </group>
          <group group_id="O2">
            <title>Responder</title>
            <description>Sitagliptin response patients</description>
          </group>
        </group_list>
        <measure>
          <title>Differences of DPP-4 Activity After Sitagliptin Treatment Between Responder and Non-responder Groups</title>
          <description>The DPP-4 activity was measured at baseline and 0, 15, 30, 45 and 60 min during the meal tolerance test. Second measurement of DPP-4 activity was measured with MTT after taking sitagliptin 100 mg 1 hour before the test. Plasma DPP-4 activity during meal tolerance test is expressed as percentage activity relative to baseline. DPP-4 activity % was calculated using the following formula : (DPP-4 activity at time t / Baseline DPP-4 activity) × 100.</description>
          <units>percentage of DPP4 activity</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" spread="0"/>
                    <measurement group_id="O2" value="100" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitagliptin 0 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.2" spread="13.2"/>
                    <measurement group_id="O2" value="40.5" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitagliptin 15 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.3" spread="18.6"/>
                    <measurement group_id="O2" value="39.2" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitagliptin 30 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.7" spread="13.1"/>
                    <measurement group_id="O2" value="38.7" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitagliptin 45 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.6" spread="18.7"/>
                    <measurement group_id="O2" value="33.5" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitagliptin 60 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.5" spread="12.5"/>
                    <measurement group_id="O2" value="44.3" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Concentration of Total GLP-1 Before and After Sitagliptin Treatment</title>
        <description>Plasma concentrations of total GLP-1 were measured at 0, 15, 30, 45, 60, 90, 120 and 180 min during the meal tolerance test. Second measurement of total GLP-1 were measured with MTT after taking sitagliptin 100 mg 1 hour before the test.</description>
        <time_frame>0, 15, 30, 45, 60, 90, 120, 180 min pre and post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-responder</title>
            <description>Sitagliptin non-response patients</description>
          </group>
          <group group_id="O2">
            <title>Responder</title>
            <description>Sitagliptin response patients</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of Total GLP-1 Before and After Sitagliptin Treatment</title>
          <description>Plasma concentrations of total GLP-1 were measured at 0, 15, 30, 45, 60, 90, 120 and 180 min during the meal tolerance test. Second measurement of total GLP-1 were measured with MTT after taking sitagliptin 100 mg 1 hour before the test.</description>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline 0 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6" spread="26.9"/>
                    <measurement group_id="O2" value="15.6" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline 15 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.5" spread="26.1"/>
                    <measurement group_id="O2" value="20.4" spread="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline 30 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.2" spread="26.8"/>
                    <measurement group_id="O2" value="22.4" spread="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline 45 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.9" spread="18.9"/>
                    <measurement group_id="O2" value="25.5" spread="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline 60 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8" spread="20.9"/>
                    <measurement group_id="O2" value="21.7" spread="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline 90 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8" spread="24.3"/>
                    <measurement group_id="O2" value="19.2" spread="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline 120 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.3" spread="22.2"/>
                    <measurement group_id="O2" value="19.9" spread="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline 180 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.5" spread="28.3"/>
                    <measurement group_id="O2" value="19.3" spread="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-dose 0 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.0" spread="27.8"/>
                    <measurement group_id="O2" value="16.4" spread="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-dose 15 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.4" spread="27.9"/>
                    <measurement group_id="O2" value="20.6" spread="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-dose 30 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3" spread="19.4"/>
                    <measurement group_id="O2" value="20.6" spread="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-dose 45 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.2" spread="27.2"/>
                    <measurement group_id="O2" value="18.9" spread="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-dose 60 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.5" spread="29.1"/>
                    <measurement group_id="O2" value="18.6" spread="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-dose 90 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2" spread="30.1"/>
                    <measurement group_id="O2" value="18.1" spread="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-dose 120 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7" spread="30.5"/>
                    <measurement group_id="O2" value="18.7" spread="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-dose 180 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.0" spread="25.8"/>
                    <measurement group_id="O2" value="18.2" spread="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Concentration of Total Glucose-dependent Insulinotropic Polypeptide (GIP) Before and After Sitagliptin Treatment</title>
        <description>Plasma concentrations of total GIP were measured at 0, 15, 30, 45, 60, 90, 120 and 180 min during the meal tolerance test. Second measurement of total GIP were measured with MTT after taking sitagliptin 100 mg 1 hour before the test.</description>
        <time_frame>0, 15, 30, 45, 60, 90, 120, 180 min pre and post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-responder</title>
            <description>Sitagliptin non-response patients</description>
          </group>
          <group group_id="O2">
            <title>Responder</title>
            <description>Sitagliptin response patients</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of Total Glucose-dependent Insulinotropic Polypeptide (GIP) Before and After Sitagliptin Treatment</title>
          <description>Plasma concentrations of total GIP were measured at 0, 15, 30, 45, 60, 90, 120 and 180 min during the meal tolerance test. Second measurement of total GIP were measured with MTT after taking sitagliptin 100 mg 1 hour before the test.</description>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline 0 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" spread="4.5"/>
                    <measurement group_id="O2" value="12.3" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline 15 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.3" spread="30.7"/>
                    <measurement group_id="O2" value="40.3" spread="28.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline 30 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.6" spread="49.9"/>
                    <measurement group_id="O2" value="60.2" spread="39.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline 45 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.6" spread="43.5"/>
                    <measurement group_id="O2" value="54.1" spread="37.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline 60 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.0" spread="22.6"/>
                    <measurement group_id="O2" value="52.0" spread="37.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline 90 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.3" spread="22.6"/>
                    <measurement group_id="O2" value="44.7" spread="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline 120 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.7" spread="27.9"/>
                    <measurement group_id="O2" value="39.0" spread="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline 180 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.9" spread="17.9"/>
                    <measurement group_id="O2" value="30.0" spread="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-dose 0 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" spread="4.0"/>
                    <measurement group_id="O2" value="10.3" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-dose 15 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.2" spread="14.0"/>
                    <measurement group_id="O2" value="26.3" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-dose 30 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.8" spread="34.7"/>
                    <measurement group_id="O2" value="33.1" spread="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-dose 45 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.6" spread="37.8"/>
                    <measurement group_id="O2" value="38.5" spread="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-dose 60 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.5" spread="26.1"/>
                    <measurement group_id="O2" value="37.7" spread="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-dose 90 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.2" spread="15.7"/>
                    <measurement group_id="O2" value="38.2" spread="41.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-dose 120 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.8" spread="15.3"/>
                    <measurement group_id="O2" value="35.0" spread="39.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-dose 180 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.8" spread="9.2"/>
                    <measurement group_id="O2" value="24.7" spread="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in AUC of Active GLP-1, Total GLP-1 and Total GIP Between Before and After Sitagliptin Treatment</title>
        <description>Plasma concentrations of active GLP-1, total GLP-1 and total GIP were measured at 0, 15, 30, 45, 60, 90, 120 and 180 min during the meal tolerance test. Second measurements were measured with MTT after taking sitagliptin 100 mg 1 hour before the test. Comparisons were made using Area under the curve (AUC) values and incremental area under the curve (ΔAUC) of active GLP-1, total GLP-1 and total GIP before and after the addition of sitagliptin.</description>
        <time_frame>0, 15, 30, 45, 60, 90, 120, 180 min pre and post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-responder</title>
            <description>Sitagliptin non-response patients</description>
          </group>
          <group group_id="O2">
            <title>Responder</title>
            <description>Sitagliptin response patients</description>
          </group>
        </group_list>
        <measure>
          <title>Change in AUC of Active GLP-1, Total GLP-1 and Total GIP Between Before and After Sitagliptin Treatment</title>
          <description>Plasma concentrations of active GLP-1, total GLP-1 and total GIP were measured at 0, 15, 30, 45, 60, 90, 120 and 180 min during the meal tolerance test. Second measurements were measured with MTT after taking sitagliptin 100 mg 1 hour before the test. Comparisons were made using Area under the curve (AUC) values and incremental area under the curve (ΔAUC) of active GLP-1, total GLP-1 and total GIP before and after the addition of sitagliptin.</description>
          <units>pmol*min/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline AUC active GLP-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2181.7" spread="1099.6"/>
                    <measurement group_id="O2" value="1578.2" spread="807.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline AUC total GLP-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5766.5" spread="4229.7"/>
                    <measurement group_id="O2" value="3680.2" spread="3209.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline AUC total GIP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10216.7" spread="4226.1"/>
                    <measurement group_id="O2" value="7575.6" spread="4608.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-dose AUC active GLP-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3898.5" spread="1547.5"/>
                    <measurement group_id="O2" value="3535.1" spread="2769.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-dose AUC total GLP-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4794.5" spread="4949.8"/>
                    <measurement group_id="O2" value="3373.6" spread="3169.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-dose AUC total GIP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8784.6" spread="2449.2"/>
                    <measurement group_id="O2" value="5929.4" spread="4711.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ΔAUC active GLP-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1716.8" spread="1350.7"/>
                    <measurement group_id="O2" value="1956.8" spread="2910.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ΔAUC total GLP-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-972.0" spread="1030.4"/>
                    <measurement group_id="O2" value="-306.7" spread="883.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ΔAUC total GIP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1432.1" spread="2738.0"/>
                    <measurement group_id="O2" value="-1646.2" spread="1817.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Non-responder</title>
          <description>Sitagliptin non-response patients</description>
        </group>
        <group group_id="E2">
          <title>Responder</title>
          <description>Sitagliptin response patients</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ji Hyun Kim</name_or_title>
      <organization>The Catholic University of Korea</organization>
      <phone>82-2-961-4534</phone>
      <email>kjhyun@catholic.ac.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

